Journal article
PDX: Moving beyond drug screening to versatile models for research discovery
GP Risbridger, MG Lawrence, RA Taylor
Journal of the Endocrine Society | ENDOCRINE SOC | Published : 2020
Abstract
Patient-derived xenografts (PDXs) are tools of the trade for many researchers from all disciplines and medical specialties. Most endocrinologists, and especially those working in oncology, commonly use PDXs for preclinical drug testing and development, and over the last decade large collections of PDXs have emerged across all tumor streams. In this review, we examine how the field has evolved to include PDXs as versatile resources for research discoveries, providing evidence for guidelines and changes in clinical practice.
Grants
Awarded by Congressionally Directed Medical Research Programs
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council, Australia (fellowship to G.P.R. 1102752; project grants to G.P.R. 1138242, and M.G.L 1156570), Department of Defense office of the Congressionally Directed Medical Research Programs through the Prostate Cancer Research Program-Impact Award (W81XWH1810349), the Department of Health and Human Services acting through the Victorian Cancer Agency (fellowships to M.G.L. MCRF18017, R.A.T. MCRF15023, CAPTIV Program), the CASS Foundation (Medical Science grant to M.G.L. 7139), the EJ Whitten Foundation, Movember (GAP Xenografting Consortium), the Peter and Lyndy White Foundation, and TissuPath Pathology.